On This Page

Filter

These are the filters currently being used to limit the search results. Click on the
icon to remove the filter.

answer › date of answer

2019-05-22

uin

HL15600

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are
shown at the top of the list. Click on to remove a sort and or to reverse the current sort order. Click on the icon to remove all the sorting. Note that sorting can significantly slow down the
loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined
views, but starred properties are always present no matter what the view. You can
star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

To ask Her Majesty's Government what analyses they have conducted of the risks and
benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1;
and whether they will publish the results any such analyses.

<p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent
expert advice on the United Kingdom’s immunisation programme. As an independent committee,
it is well placed to ensure the latest and most appropriate evidence has been considered
on potential changes to scheduling within the vaccine programme. It bases its advice
on review of a wide range of scientific and other evidence, including from the published
literature, commissioned studies such as independent analyses of vaccine effectiveness
and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant
pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice
takes into account the public health aspects of any potential change to the vaccination
schedule, such as the potential impact on cases of infectious disease. The JCVI consulted
relevant stakeholders on its proposed advice, between January and April 2018, to ensure
that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal
programme was given full consideration, including the potential public health implications,
before a decision was made to implement it. The UK frequently adopts innovative immunisation
schedules and we regularly change the vaccine schedule following the advice of our
independent expert committee, as we are doing in this case.</p><p>The decision is
based on the excellent effectiveness of the vaccine and years of high uptake, which
has helped to provide protection to the rest of the population and has successfully
controlled many types of pneumococcal disease in this country. The evidence shows
that two doses will sustain the excellent results we have already seen. We are confident
that the world-class disease surveillance system we have in this country means our
expert committee can closely monitor the impact of this change. This is set out in
the JCVI’s minutes which are attached.</p>